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worse, and 2 – cosmesis two categories worse after 
radiotherapy. For the subjective score the median difference 
for the 3 observers was considered. At submission of this 
abstract 2-year cosmetic outcome was available for 82/100 
patients (39 prone and 43 supine treated). All patients will 
have reached 2-year follow up in January 2014 and final 
results will be available for presentation at the 3rd ESTRO 
Forum. 
Results: Patient and treatment characteristics were not 
significantly different between both cohorts. Figure 1 shows 
the interim data. Neither objective, nor subjective cosmetic 
outcome was significantly different between prone and 
supine treated patients. On the photographs with the hands 
up, more patients in the supine group had a worsening of 
cosmesis of 2 categories using the BCCT.org software (6/43 
versus 0/39 in the prone cohort, p = 0.053). 
 
Conclusions: Interim analysis shows no significant differences 
in cosmetic outcome between prone and supine WBI after a 
limited follow-up of 2-year. Final data will be presented at 
the 3rd ESTRO Forum.  
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Purpose/Objective: To investigate heart position 
reproducibility on cone-beam CT (CBCT) during voluntary 
moderate deep inspiration breath-hold (mDIBH) for 
radiotherapy of left-sided breast cancer patients. 
Materials and Methods: For 20 consecutive left-sided breast 
cancer patients, FB and mDIBH CT datasets were acquired. 
Both scans were registered on the breast and chest wall. 
Heart position with respect to chest wall (HP-CW) was 
measured on both scans in the transversal slice where the 
heart was nearest to the chest wall at the level of the 
tangential fields, i.e. nearest to the field edge of the 
treatment beams, perpendicular to the tangential field edge. 
The change in HP-CW on the FB scan relative to the mDIBH 
scan was quantified as ΔHP-CW. Treatment planning was based 
on the mDIBH CT scan. For 50 additional consecutive 
patients, who are treated with tangential IMRT beams, CBCT 
scans were made during mDIBH for position verification and 
setup correction. During treatment breath-hold was 
monitored using an in-house developed tool, resulting in an 
accurate and reproducible position of the breast and chest 
wall during mDIBH. On the CBCT scans the difference in heart 
position with respect to the reference mDIBH CT was 
measured after registration, in order to quantify the change 
in heart position relative to the chest wall (ΔHP-CW). 
Results: On the FB scan heart position was on average 10.8 ± 
5.1 mm (range 3.5 – 21.7 mm) closer to the chest wall 
compared to the mDIBH scan (indicated as a negative ΔHP-CW 
in Figure 1). Despite the breath-hold, the heart was on 
average 4.7 ± 8.3 mm (range -21 – +12 mm) inside the 
radiation field on the initial planning mDIBH CT scan.  
At fraction 1, the average ΔHP-CW was -0.8 ± 5.2 mm, i.e. the 
breath-hold was less deep than during planning CT. During 
the total treatment, the average ΔHP-CW was 0.9 ± 4.4 mm 
(range -8.3 – +10.4 mm, Figure 1), suggesting a trend towards 
progressively deeper inspiration during the rest of the 
treatment course. However, there was a large interfraction 
variation per patient in ΔHP-CW over the treatment course with 
an average standard deviation of 3.1 mm. 
 
 
Figure 1: Distribution of ΔHP-CW between FB and mDIBH CT-
scan (red, n=20), and average ΔHP-CW between CBCT and 
mDIBH CT (blue, n=50). 
 
Conclusions: In this study, applying voluntary mDIBH always 
decreased the amount of heart inside the treatment volume. 
Despite the large interfraction variation, on average the 
distance between heart and chest wall increased during 
treatment. Therefore, voluntary mDIBH is sufficient for the 
majority of the patients, although some patients might 
benefit from an online feature that monitors both chest wall 
and heart position during breath-hold.  
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Purpose/Objective: Patients (pts) with locally advanced soft 
tissue sarcoma of the extremities or trunk wall are frequently 
treated with neo-adjuvant treatment followed by wide 
resection. Pre-operative radiotherapy (RT) is one of these 
validated options. To optimize outcome, NBTXR3, 
functionalized hafnium oxide nanoparticles, have been 
developed as selective radioenhancer, which may represent a 
breakthrough approach for the local treatment of solid 
tumors. The high electron density of NBTXR3 nanoparticles 
when exposed to radiotherapy, may allow 
absorption/deposition of a high energy dose within the 
cancer cell, and possibly improve outcome. 
Materials and Methods: Pts received a single intratumor (IT) 
injection of NBTXR3 at fixed concentration (53.3 g/L), 
volume escalated from level 1 (2.5% of tumor volume) to 
level 4 (20% of tumor volume), followed by RT (50 Gy in 25 
fractions of 2 Gy over 5 weeks). Primary endpoints include 
feasibility of the IT implantation and safety. Secondary 
endpoints focus on efficacy such as pathological and RECIST 
response, IT residency of NBTXR3 over the whole RT time, 
and operability. 
Results: Out of 21 pts included, 20 are evaluable: they 
underwent a wide surgical resection and received the 
planned radiotherapy. Feasibility of the IT injection was 
confirmed. The treatment was safe. Main grade 1-2 toxicities 
related to NBTXR3 were injection pain/reaction (4 pts), fever 
(2 pts), abdominal pain (1 pt), pruritus (1 pt) and paresthesia 
(1 pt). At volume 20%, 2 pts had grade 3 pain at the injection 
site. Results demonstrate that one injection of NBTXR3 
provides adequate bioavailability of NBTXR3 over five weeks 
of radiotherapy. No leakage of NBTXR3 to the adjoining 
healthy tissues was observed. Further, NBTXR3 persistence 
was established by CT scan before surgery. At Volumes 
2.5%,5%,10%, and 20%, the median change in sarcoma volume 
was respectively 13%; 40%, 44% and 51%. The percentage of 
residual and viable cells was 34% at the chosen maximum 
tolerated 10% level of tumour volume.  
Conclusions: Injection of NBTXR3 was very well tolerated 
until 10% of tumor volume. NBTXR3 with preoperative RT 
seems to be an effective neo-adjuvant treatment for pts with 
locally advanced STS. An international phase II/III will start in 
the Q4 2014. The recommended volume is 10% of tumor 
volume, for this prospective study comparing this 
investigational treatment to pre-operative RT  
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Purpose/Objective: The role of pelvic elective nodal 
irradiation (ENI) in the management of prostate cancer is still 
controversial. Despite negative clinical trials, clinical 
practices vary greatly, even in patients at high risk of pelvic 
lymph node dissemination. The aim of this study was to 
analyze the role of pelvic radiotherapy on the outcome in 
high-risk localized prostate cancer patients included in the 
recently reported GETUG 12 trial (Fizazi et al, ASCO 2014). 
Materials and Methods: Eligibility criteria included non-
pretreated high-risk localized CaP, defined as one or more of 
the following criteria: T3-T4, Gleason score (GS)>7, PSA>20 
ng/mL, pN+ (stratification factors). All pts had a staging 
pelvic lymph node dissection. Pts were randomly assigned to 
either goserelin 10.8 mg every 3 months for 3 years and 4 
cycles of docetaxel 70 mg/m2 q3w + estramustine 10 
mg/kg/d d1-5 (ADT+DE arm) or goserelin alone (ADT arm). 
Local therapy was administered 3 months after the start of 
hormonal treatment. The performance of pelvic ENI was left 
to the treating physician and was performed using 3D 
conformal radiotherapy. Median dose was 46 Gy in 2 Gy 
fractions. Only patients treated with primary radiotherapy 
are included in this analysis. Multivariate Cox model was used 
to look for an association between pelvic ENI and biochemical 
progression free survival (bPFS). Adjustment factors were: 
PSA level, T stage, Gleason score, pN stage. 
Results: 413 patients were included from 2002 to 2006, out 
of which 358 were treated using primary radiotherapy and 
are analyzed in the present report. 208 patients received a 
pelvic radiotherapy and 150 prostate-only. PSA level, Gleason 
score or T stage did not differ according to the performance 
of pelvic radiotherapy. However pN+ patients more 
frequently received pelvic radiotherapy than pN0 patients 
(pelvic ENI 89% in pN+ pts and 47% in pN0 pts; p 
Conclusions: This unplanned analysis of a recently completed 
trial failed to demonstrate a benefit of pelvic radiotherapy in 
high-risk localized prostate cancer patients. bPFS was 
negatively impacted by pN+ and positively impacted by 
chemotherapy in GETUG 12 patients treated by radiotherapy.  
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Purpose/Objective: To report the grade 3 and higher (G3+) 
GU and GI toxicity for patients in a randomized trial 
evaluating the efficacy and safety of two different 
techniques for achieving dose escalation. 
Materials and Methods: 398 men with National 
Comprehensive Cancer Network (NCCN) intermediate-risk 
(N=122) or high-risk (N=276) localized prostate cancer were 
accrued at 6 centers, stratified by risk group and randomized 
to one of two treatment arms. Both arms received 12 months 
of androgen deprivation therapy (ADT via LHRH depot 
injections), 8 months of which was given prior to starting 
whole pelvic irradiation (46Gy/23/#s). Patients randomized 
to the dose-escalated external beam arm (DE-EBRT, N=200) 
continued with a 3-d conformal boost to the prostate of 
32Gy/16#s. Patients randomized to the low-dose-rate 
Brachytherapy arm (LDR-PB, N=198) had an 125Iodine implant 
(MPD = 115Gy). Physician-scored toxicity was prospectively 
assessed and recorded using a modified LENT-SOMA scoring 
system. Follow up (FU) times for the toxicity data was 
calculated from the date of the start of Radiation treatment. 
The primary endpoint of the trial was disease free survival 
(DFS). There were 12 major protocol violations in each arm; 
all results are reported on an intent-to-treat basis. 
Results: Patients randomized to LDR-PB were more than 
twice as likely to be disease-free at median FU of 6.5 yrs 
(hazard ratio = 2.11; 95% CI 0.1.31 – 3.42; P = 0.0022). Acute 
